Kerry Group Acquires Majority Stake in c-LEcta GmbH

Merck KGaA to Acquire Bio-Techne for $11.3 Billion

June 25, 2026

Healthcare Services

Merck KGaA has entered a definitive agreement to acquire Bio-Techne for $73 per share in an all-cash transaction valued at about $11.3 billion (enterprise value). The deal is expected to close in late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval.

Eli Lilly Acquires Kelonia Therapeutics for Up to $7 Billion

April 20, 2026

Biotechnology

Eli Lilly has announced a definitive agreement to acquire Kelonia Therapeutics, a clinical-stage biotechnology company developing in vivo CAR-T cell therapy via its proprietary gene delivery platform. The deal is valued at up to $7 billion, including a $3.25 billion upfront payment, with additional clinical, regulatory, and commercial milestone payments. Closing is expected in the second half of 2026, subject to customary approvals.

Kemin Industries Acquires CJ Youtell Biotech

September 23, 2025

Biotechnology

Kemin Industries has acquired CJ Youtell Biotech, the enzymes and fermentation subsidiary of CJ Bio, gaining full ownership of CJ Youtell’s fermentation plants and enzyme product portfolio. The acquisition adds fermentation capacity in Shandong and Hunan, China and expands Kemin’s global enzyme R&D, manufacturing and product offerings across animal feed, food, aquaculture and industrial end markets.

Kerry Group to Acquire Lactase Enzyme Business from Chr. Hansen and Novozymes

December 14, 2023

Food & Beverage

Kerry Group PLC has agreed to acquire part of the global lactase enzyme business carved out from Chr. Hansen Holding A/S and Novozymes A/S for a total consideration of €150 million (subject to closing adjustments). The deal includes certain trade and assets of Chr. Hansen's global lactase business and 100% of Nuocheng Trillion Food (Tianjin) Co., Ltd.; the lactase business generated about €40 million in revenue in 2022 and the transaction is expected to close in the first half of 2024 subject to European Commission approval.

Accel-KKR Takes Majority Stake in Lemontech

June 28, 2019

Cloud & SaaS

Accel-KKR has made a majority investment in Lemontech, the Santiago-based legaltech SaaS provider, to accelerate the company's international expansion, product development and talent growth. As part of the transaction, Accel-KKR principals will join Lemontech’s board and provide strategic and operational support to scale the business across Latin America and beyond.

Canopy Biosciences Acquires Zellkraftwerk GmbH

April 29, 2019

Biotechnology

Canopy Biosciences acquired Leipzig-based Zellkraftwerk GmbH, adding Zellkraftwerk’s ChipCytometry multiplex cytometry instruments and related services to Canopy’s multi-omics portfolio. Concurrently, Ampersand Capital Partners made a strategic growth investment in Canopy to support geographic expansion and product/service scale-up across the US, Europe and Asia.